STOCK TITAN
  1. Home
  2. News
  3. ICLR

ICON Public Limited Company - $ICLR STOCK NEWS

Welcome to our dedicated page for ICON Public Company news (Ticker: $ICLR), a resource for investors and traders seeking the latest updates and insights on ICON Public Company stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ICON Public Company's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ICON Public Company's position in the market.

News
BARDA Partners With ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
Rhea-AI Summary
ICON plc partners with BARDA to conduct clinical trial for next generation COVID-19 vaccine candidates
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.04%
Tags
partnership clinical trial covid-19
-
News
ICON plc to Present at the Baird Global Healthcare Conference
Rhea-AI Summary
ICON plc CEO to present at Baird Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
conferences
-
News
ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) Announces Successful Passing of All Resolutions at the Annual General Meeting, Including Re-election of Board Members and Authorization for Share Allotment and Market Purchases
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
none
News
ICON Reports Second Quarter 2023 Results
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) reported net business wins of $2,419 million in Q2 2023, with a closing backlog of $21.7 billion. Quarter two revenue increased by 4.4%, and adjusted EBITDA rose by 16.9%. The company updated its full-year 2023 financial guidance, expecting revenue in the range of $8,070 - $8,210 million, representing a year-over-year increase of 4.3 to 6.1%, and adjusted earnings per share in the range of $12.63 - $12.91, reflecting a year-over-year increase of 7.5 to 9.9%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.53%
Tags
earnings
-
News
First Half of 2023 Sees ICON Recognised for CRO Excellence, Alongside Industry Awards as an Employer of Choice and for Its Creative and Digital Services
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) received multiple awards in 2023, including the 2023 CRO Leadership Awards for Capabilities, Compatibility, Expertise, Quality, and Reliability. They were also recognized as a top employer and received the 2023 Global Impact Award for their role in the search for COVID-19 vaccines and treatments. CEO Steve Cutler emphasized the importance of driving positive outcomes and value for customers and patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
-
News
ICON plc Schedules Second Quarter 2023 Earnings Conference Call
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.96%
Tags
earnings
News
ICON Releases Latest Version of its Digital Platform, Providing Integrated Patient Services and Harmonised Data in One Platform
Rhea-AI Summary
ICON plc announces the latest release of its Digital Platform, which supports greater patient centricity and speed in study start-up for clinical trials. The platform offers seamless integration of patient, site, and sponsor services, and can be customized for any study design and therapeutic area. It includes features such as an easy-to-use patient mobile app, eConsent, eCOA, direct data capture for in-home services, televisits, and digital health technology management. The platform also provides concierge services to support users, reduces regulatory compliance risk, and enables interoperability of key operational systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
News
ICON plc Set to Join Russell 3000® Index
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
-
News
ICON plc to Attend Upcoming Investor Conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.19%
Tags
conferences
News
ICON releases its 2022 ICON Cares ESG Report
Rhea-AI Summary
ICON plc releases its ICON Cares 2022 Environmental, Social and Governance (ESG) Report, highlighting its progress in advancing its ESG priorities. The report focuses on ICON's efforts in advancing public health, increasing access to clinical trials, creating an inclusive workplace, conducting business sustainably, and supporting communities. ICON was awarded a silver medal by EcoVadis for its ESG efforts. The company has also signed its commitment letter to the Science Based Targets initiative to reduce GHG emissions. For more information, visit ICON's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
Stock ICLR logo
ICON Public Limited Company

Nasdaq:ICLR

ICLR Rankings

#419 Ranked by Market Cap
#950 Ranked by Stock Gains
N/A Ranked by Dividends

ICLR Stock Data

26.52B
81.31M
0.66%
101.49%
1.68%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Dublin 18

About ICLR

icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. we specialise in the strategic development, management and analysis of programmes that support clinical development - from compound selection to phase i-iv clinical studies. in a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. we have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. we are also an 'end-to-end'​ pharmacovigilance service provider and this includes post marketing surveillance activities too.